Oncotarget

The podcast explores the potential of melatonin as a treatment for cancer, discussing its effects on tumor growth, anti-cancer therapies, metastasis, and inflammatory processes. It also delves into the mechanisms and clinical applications of melatonin in cancer treatment, emphasizing the importance of timing and the need for further research.

The podcast explores the potential of a CDK9 inhibitor, GfH009, for treating hematologic malignancies. It discusses GfH009's mechanism of action, anti-cancer activity, and its potential as a targetable vulnerability in various hematologic malignancies.

The podcast discusses the management of refractory or relapsed classic Hodgkin lymphoma in Brazil, exploring the challenges in treatment decisions and the impact of novel agents like Brentuximab vedotin and immunotherapy.

The podcast discusses the inhibitory effect of melatonin on mammary tumors in mice, highlighting a study conducted 50 years ago. It explores the effects of melatonin administration on chemically induced mammary carcinogenesis in mice and rats. The timing of melatonin administration is crucial and it has potential as a valuable drug in oncology.

Researchers discuss the development of drug resistance and the role of cancer stemness in colorectal cancer. They propose a triple combination treatment to overcome resistance. Clinical trial findings show that this treatment suppresses cancer cell growth, targets drug resistance mechanisms, and improves treatment outcomes in colorectal cancer patients.

Dr. Georg F. Weber, a researcher from the University of Cincinnati, talks about his research paper on 'Osteopontin induces mitochondrial biogenesis in deadherent cancer cells'. He discusses the unique metabolism of metastasizing cells and their preference for glycolysis. The chapter also explores the connection between mitochondrial activation and biogenesis in cancer cells, with a focus on the role of osteopontin. Additionally, peroxide production in cancer cells and its impact on cancer metastasis is discussed, revealing surprising findings about the involvement of mitochondrial decoupling and SLC7A11 channel.

This podcast discusses the therapeutic potentials and challenges of cytostatic persister cancer cells. They explore the properties of these cells and strategies to target and reduce their presence, emphasizing the importance of administering multiple targeted regimens.

Researchers from Assuta Medical Center and Ben-Gurion University of the Negev discuss their systematic review on the risk factors for arm morbidities following breast cancer treatments. They reveal 29 identified risk factors and emphasize the significance of understanding these factors for rehabilitation treatments.

A new research paper explores the correlation between plasma levels of BCMA-positive extracellular vesicles (EV) and the response/side effects of myeloma patients on Belantamab-Mafodotin therapy. BCMA-EV levels were significantly higher in patients prior to therapy and showed a significant increase during treatment. Measuring BCMA-EV levels could help identify resistance mechanisms and side effects of BCMA-targeted therapies.

This podcast explores the relationship between Osteopontin splice variants and mitochondrial biogenesis in cancer cells, revealing a functional connection between short-term oxidative metabolism and long-term mitochondrial biogenesis, with potential implications for treating cancer metastasis.